{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:55:38Z","timestamp":1789419338143,"version":"build-2803163510"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>The role of the beta-adrenergic signaling pathway in heart failure (HF) is pivotal. Early blockade of this pathway with beta-blocker (BB) therapy is recommended as the first-line medication for patients with HF and reduced ejection fraction (HFrEF). Conversely, in patients with severe acute HF (AHF), including those with resolved cardiogenic shock (CS), BB initiation can be hazardous. There are very few data on the management of BB in these situations. The present expert consensus aims to review all published data on the use of BB in patients with severe decompensated AHF, with or without hemodynamic compromise, and proposes an expert-recommended practical algorithm for the prescription and monitoring of BB therapy in critical settings.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1263482","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T12:03:57Z","timestamp":1700136237000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Beta-blocker management in patients admitted for acute heart failure and reduced ejection fraction: a review and expert consensus opinion"],"prefix":"10.3389","volume":"10","author":[{"given":"Guillaume","family":"Schurtz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Mewton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Lemesle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Delmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Puymirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Aissaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Gerbaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bochaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bonnefoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Roubille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Lamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet Lond Engl"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet Lond Engl"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure","volume":"43","author":"Gattis","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJM198207223070401","article-title":"Decreased catecholamine sensitivity and \u03b2-adrenergic-receptor density in failing human hearts","volume":"307","author":"Bristow","year":"1982","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1136\/hrt.37.10.1022","article-title":"Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy","volume":"37","author":"Waagstein","year":"1975","journal-title":"Heart"},{"key":"B9","doi-asserted-by":"publisher","first-page":"26l","DOI":"10.1016\/S0002-9149(97)00846-1","article-title":"Mechanism of action of beta-blocking agents in heart failure","volume":"80","author":"Bristow","year":"1997","journal-title":"Am J Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/S0735-1097(00)01006-8","article-title":"Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure","volume":"36","author":"Groenning","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1161\/01.CIR.79.3.483","article-title":"Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy","volume":"79","author":"Heilbrunn","year":"1989","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/ejhf.775","article-title":"Prognostic role of \u03b2-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database: \u03b2-blockers and heart failure: insights from the MECKI score database","volume":"19","author":"Paolillo","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B13","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1001\/jama.289.6.712","article-title":"Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study","volume":"289","author":"Krum","year":"2003","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.2252","article-title":"Treatment patterns and clinical outcomes among patients <65 years with a worsening heart failure event","volume":"23","author":"Butler","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0002-9343(78)90707-6","article-title":"Hospital treatment of congestive heart failure","volume":"65","author":"Forrester","year":"1978","journal-title":"Am J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/S0735-1097(03)00309-7","article-title":"Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure","volume":"41","author":"Nohria","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1161\/hc1002.105180","article-title":"Tolerability of \u03b2-blocker initiation and titration in the metoprolol CR\/XL randomized intervention trial in congestive heart failure (MERIT-HF)","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jchf.2015.03.008","article-title":"Effects of beta-blocker withdrawal in acute decompensated heart failure","volume":"3","author":"Prins","year":"2015","journal-title":"JACC Heart Fail"},{"key":"B21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.ejheart.2007.05.011","article-title":"Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET","volume":"9","author":"Metra","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"B22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0002-9149(02)03104-1","article-title":"Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure","volume":"91","author":"Gattis","year":"2003","journal-title":"Am J Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/CCM.0b013e31820a91ed","article-title":"Beneficial association of \u03b2-blocker therapy on recovery from severe acute heart failure treatment: data from the survival of patients with acute heart failure in need of intravenous inotropic support trial*","volume":"39","author":"B\u00f6hm","year":"2011","journal-title":"Crit Care Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.acvd.2019.04.004","article-title":"Predictive factors for long-term mortality in miscellaneous cardiogenic shock: protective role of beta-blockers at admission","volume":"112","author":"Delmas","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13054-021-03706-2","article-title":"Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial","volume":"25","author":"Di Santo","year":"2021","journal-title":"Crit Care"},{"key":"B26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/eurjhf\/hfn045","article-title":"Levosimendan vs. dobutamine: outcomes for acute heart failure patients on \u03b2-blockers in SURVIVE\u2020","volume":"11","author":"Mebazaa","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S0735-1097(02)02134-4","article-title":"Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure","volume":"40","author":"Metra","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ccd.28329","article-title":"SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American college of cardiology (ACC), the American heart association (AHA), the society of critical care medicine (SCCM), and the society of thoracic surgeons (STS) in April 2019","volume":"94","author":"Baran","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"B30","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ehf2.13734","article-title":"Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: insights from the FRENSHOCK registry","volume":"9","author":"Delmas","year":"2022","journal-title":"ESC Heart Fail"},{"key":"B31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jchf.2017.09.023","article-title":"Integrative assessment of congestion in heart failure throughout the patient journey","volume":"6","author":"Girerd","year":"2018","journal-title":"JACC Heart Fail"},{"key":"B32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijcard.2011.05.051","article-title":"Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving beta-blockers: insights from the BEST trial","volume":"163","author":"Desai","year":"2013","journal-title":"Int J Cardiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s10557-020-07124-4","article-title":"Ivabradine in cardiovascular disease management revisited: a review","volume":"35","author":"Chen","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/ehf2.12499","article-title":"Initiation of ivabradine in cardiogenic shock","volume":"6","author":"Chiu","year":"2019","journal-title":"ESC Heart Fail"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/S0735-1097(98)00077-1","article-title":"Combined oral positive inotropic and Beta-blocker therapy for treatment of refractory class IV heart failure","volume":"31","author":"Shakar","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejheart.2006.06.001","article-title":"Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure","volume":"9","author":"Berger","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"B37","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1067\/mhj.2001.117605","article-title":"Carvedilol titration in patients with congestive heart failure receiving inotropic therapy","volume":"142","author":"Kumar","year":"2001","journal-title":"Am Heart J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/ejhf.39","article-title":"Weaning from inotropic support and concomitant beta-blocker therapy in severely ill heart failure patients: take the time in order to improve prognosis: weaning from inotropic support and concomitant beta-blocker therapy","volume":"16","author":"Constantinescu","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"B39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1124\/jpet.116.232884","article-title":"Comparison of the -adrenergic receptor antagonists landiolol and esmolol: receptor selectivity, partial agonism, and pharmacochaperoning actions","volume":"359","author":"Nasrollahi-Shirazi","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"A19","DOI":"10.1093\/eurheartj\/sux035","article-title":"Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction","volume":"20","author":"Haehling","year":"2018","journal-title":"Eur Heart J Suppl"},{"key":"B41","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jchf.2018.10.014","article-title":"NT-proBNP goal achievement is associated with significant reverse remodeling and improved clinical outcomes in HFrEF","volume":"7","author":"Daubert","year":"2019","journal-title":"JACC Heart Fail"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.105.582320","article-title":"Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized cardiac insufficiency bisoprolol study (CIBIS) III","volume":"112","author":"Willenheimer","year":"2005","journal-title":"Circulation"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"CD012721","DOI":"10.1002\/14651858.CD012721.pub2","article-title":"Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction","volume":"6","author":"Martin","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers in heart failure collaborative group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1263482\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T12:03:59Z","timestamp":1700136239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1263482\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":48,"alternative-id":["10.3389\/fcvm.2023.1263482"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1263482","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"article-number":"1263482"}}